Abstract
The market for antituberculosis drugs is reviewed briefly and an estimate is formed of the potential US market for a new and improved tuberculosis vaccine. By 2010, global sales of all antituberculosis drugs are expected to reach $US612-670 million annually. An urgent need for better antituberculosis drugs exists that could permit a shorter course and less frequent dosing so that tuberculosis treatment regimens could scale up more rapidly. Should a more effective tuberculosis vaccine become available, there are approximately 18 million high-risk individuals in the USA alone for whom the vaccine would be demonstrably cost-beneficial. The high-risk groups include healthcare workers, military personnel, HIV-infected individuals, migrant farm workers and prisoners.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 775-781 |
| Number of pages | 7 |
| Journal | Expert Review of Pharmacoeconomics and Outcomes Research |
| Volume | 5 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2005 |
Keywords
- BCG
- DOTS
- Directly observed therapy short course
- High-risk groups
- Immunization
- Market
- TB
- TB vaccine
- Tuberculosis
ASJC Scopus subject areas
- Health Policy
- Pharmacology (medical)